Test Catalog

Test ID: FPAIG    
Plasminogen Activator Inhibitor-1, 4G/5G Genotyping (PAI-1 Polymorphism)

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

The PAI-1 4G allele is an inherited characteristic. If the polymorphism is present in a heterozygous or homozygous fashion, we recommend that the patient and their family consider genetic counseling to obtain additional information on inheritance and to identify other family members at risk.

If a patient possesses two or more congenital or acquired risk factors, the risk of disease may rise to more than the sum of the risk ratios for the individual risk factors. For instance, a combination of the 4G/4G genotype and the insulin resistance syndrome may confer an increase in cardiovascular disease risk over that conferred by the presence of an isolated PAI-1 4G/4G polymorphism.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Genetic testing by PCR provides exceptionally high sensitivity and specificity. Incorrect genotyping results can be caused by rare polymorphisms in primer binding sites and to misidentification of specimens by collectors or laboratory personnel. This assay analyzes only the PAI 4G/5G locus and does not measure genetic abnormalities elsewhere in the genome.

Clinical Reference Recommendations for in-depth reading of a clinical nature

Barcellona D. Thromb Haemost. 2003;90:1061.;Dossenbach-Glaninger. Clin Chem. 2003;49:1081.; Kohler et al. NEJM. 200;342:1792.; Margaglione M et al. Arterioscl Thromb and Vasc Bio. 1998;18:152.